This segment focuses on developing and commercializing therapies for patients suffering from life-threatening conditions in critical care settings. The lead product, GIAPREZA (angiotensin II), is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shock. Research and development efforts are directed towards expanding the applications of GIAPREZA and identifying new targets for hemodynamic support. The segment addresses the unmet need for effective treatments in managing acute hypotension and improving patient outcomes in intensive care units. Future opportunities include exploring combination therapies and developing novel formulations for enhanced delivery and efficacy. Regulatory and clinical strategies are focused on securing additional indications and expanding market access.

This segment is dedicated to the development and commercialization of antibacterial therapies to combat serious infections. The primary product, XERAVA, is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older. Research and development efforts are focused on developing novel antibacterial agents to address the growing threat of antimicrobial resistance. This includes TP-6076, an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria, and TP-271, an IV and oral formulation of a fully synthetic fluorocycline for the treatment of respiratory disease caused by bacterial biothreat and antibiotic-resistant public health pathogens. The segment aims to provide effective treatment options for patients with severe infections and contribute to the global fight against antibiotic resistance.

This segment is focused on the development of novel therapies for the treatment of hematological malignancies. The lead product candidate, TP-2846, is an IV formulation of a tetracycline for the treatment of acute myeloid leukemia (AML). Research and development efforts are directed towards identifying and validating new targets in AML and other blood cancers. The segment utilizes advanced molecular biology and preclinical models to evaluate the efficacy and safety of TP-2846 and other potential drug candidates. The goal is to provide innovative treatment options for patients with AML and improve survival rates. Future opportunities include exploring combination therapies with existing chemotherapeutic agents and developing personalized treatment strategies based on patient-specific genetic profiles. Regulatory and clinical strategies are focused on securing orphan drug designation and accelerating clinical development through collaborations with leading cancer centers.